Kyowa Kirin Co., Ltd. (KYKOF) Stock Price & Analysis
Kyowa Kirin Co., Ltd. (KYKOF) — price $16.20 (0.00%), as of the Nov 20, 2026 trading session; market cap $8.48B.
Educational signal · not a buy or sell recommendation · How to read this
Kyowa Kirin Co., Ltd. · KYKOF
Kyowa Kirin Co., Ltd. is a global specialty pharmaceutical company focused on oncology, nephrology, central nervous system, and immunology. The company develops and markets a range of pharmaceutical products, including treatments for breakthrough cancer pain, allergies, hypertension, and various other diseases.
Price as of Nov 20, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $16.20 | |
| Change on the day | 0.00% | |
| 52-week range | $4.20 – $18.00 | |
| Market capitalisation | $8.48B | — |
| Price / earnings (trailing) | 15.53 | |
| Shares traded on the day | 158 |
Price & events
Other perspectives
Council score for Kyowa Kirin Co. (KYKOF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 21, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 19, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Kyowa Kirin Co. (KYKOF), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Kyowa Kirin Co., Ltd. (KYKOF) is the company analyzed here. It employs 5,161 people and is led by Abdul Hafeez Mullick. The market values it at $8.48B.
What are the financial strengths and risks for Kyowa Kirin Co. (KYKOF)?
Short answer · as of
The distress and quality screens read Altman Z 6.39 · Piotroski F 6. Trailing ratios: ROE 9.8% · ROA 5.5% · current ratio 3.21.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held KYKOF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported KYKOF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Kyowa Kirin Co. (KYKOF)?
Common Questions About KYKOF
These answers are editorial: 1 of these 8 answers is drawn from the KYKOF research dossier (written Mar 17, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is KYKOF a good stock to buy?
Stock Expert AI does not rate KYKOF buy, sell or hold. Kyowa Kirin Co., Ltd. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the KYKOF stock price today?
The last price recorded for Kyowa Kirin Co., Ltd. (KYKOF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for KYKOF?
Kyowa Kirin faces several risks, including competition from biosimilars and generic drugs, which could erode market share and pricing power.
What are the key factors to evaluate for KYKOF?
Evaluate KYKOF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Not financial advice.
How frequently does KYKOF data refresh on this page?
KYKOF's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven KYKOF's recent stock price performance?
Kyowa Kirin Co., Ltd. (KYKOF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong focus on specialized therapeutic areas. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider KYKOF overvalued or undervalued right now?
The trailing P/E of Kyowa Kirin Co., Ltd. (KYKOF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research KYKOF before investing?
Before investing in Kyowa Kirin Co., Ltd. (KYKOF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 11 figures on this page — 6 from Financial Modeling Prep (FMP) and 5 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com